

## FORM 7

### MONTHLY PROGRESS REPORT

Name of Listed Issuer: Luminor Medical Technologies Inc. (the "Issuer").

Trading Symbol: LMT \_\_\_\_\_

Number of Outstanding Listed Securities: 34,498,340 \_\_\_\_\_

Date: January 31, 2018 \_\_\_\_\_

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

#### **General Instructions**

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

#### **Report on Business**

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

**The operates in two segments through two subsidiaries: Jamaica-Blu Ltd. ("JBlu") and Scout Assessment Corp. ("SACorp").**

**JBlu holds the exclusive Canadian licence of all current and future cannabis commercial products developed by Rise Research Inc. (“RISE”). RISE’s cannabis commercial products are based on a patent pending formula, currently filed with the U.S. Patent and Trademark Office, to create precise cannabis-based formulations that may produce specifically targeted effects for various ailments including diabetes. Currently, RISE’s portfolio consists of cannabis-based formulations which support patients with low libido called Jamaica blū and Jamaica pnk. The Company plans to launch its JBlu operations for medical use in Canada in Q1 2018 with the anticipation of the recreational use of cannabis in Canada in Q3 2018.**

**SACorp owns the company’s Scout DS® technology. The Scout DS®, which in 90 seconds rapidly tests individuals without blood draw or the need to fast, provides immediate results and is indicated for use for the non-invasive screening of individuals 18 years or older that are at risk for pre diabetes and/or type 2 diabetes. The Scout DS® has received clearance from Health Canada for commercial distribution, has been CE Marked in the European Union, and is also cleared for sale in other markets. Commercial piloting of the technology has taken place in Canada, and preliminary distribution channels have also been established or advanced prior to the Company’s involvement with the technology including in countries that may recognize Health Canada and CE regulatory clearances such as Saudi Arabia, Qatar, the United Arab Emirates, India, Jordan, Brazil, Turkey and Kuwait.**

2. Provide a general overview and discussion of the activities of management.

**JBlu’s objectives are to be recognized as a leading and trusted brand in the industry in Canada. The Company plans to commence the selling of products, through a licenced producer, into the ACMPR (medical) in Canada by April 1, 2018. The Company plans to commence the selling of products, through a licenced producer, into the adult use market in Canada by program launch day which is anticipated to be July 1, 2018. The Company plans to have 10,000 participants in clinical study by September 30, 2018.**

**SACorp’s business plan includes validating qualified licensing partners who will be responsible to invest in developing geographically defined markets under the guidance and direction of the Company. Since the Company acquired the Scout DS®, several pilots have been conducted by the Company in the pharmacy and employee workplace screening market segments. The Company will use the data, experience and knowledge it has gained about these market segments in order to provide general direction and guidance to newly established licensing partners. The new licensees would be responsible for all market development costs for their**

**given territory and all costs related to regulatory approval in any given market (if required) under the direction of the Company.**

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**N/A**

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**N/A**

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**RISE Research Inc. ("RISE") (see point 7 below) entered into a comprehensive strategic partnership with Constance Therapeutics ("CT"), an established San Francisco-based developer and manufacturer of premium medical cannabis extract products for physician and patient use in California.**

**The partnership includes a distribution agreement that will see RISE build and manage a retail sales and distribution channel for both CT and RISE products in the California market. RISE will deploy a direct sales team in the state to sign top-tier dispensaries, augmented by a personalized support program for customers and patients to be delivered at the store level. RISE expects to create a network of at least 240 premium store locations in California within the next 12 months.**

**Leveraging its pharmaceutical grade product, know-how, and intellectual property ("IP") assets, combined with RISE's patent pending formulation, CT will produce a product line of sexual health and wellness products under license for RISE, to be sold in California. The product line will be developed at CT's San Francisco lab and manufacturing headquarters and will be available in California retail channels in April 2018. Following the initial rollout, RISE plans to expand product sales to other U.S. states, as well as European markets.**

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**N/A**

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**During the month, the Company announce it has executed an agreement (the "Agreement") to acquire 100% of the issued and outstanding shares of RISE Research Inc. ("RISE Research"). Currently, the Company holds an exclusive Canadian license for cannabisbased consumer products developed by RISE Research, and now seeks to expand its participation and reach with this acquisition. The Company plans to be positioned well within the most active marketplaces the Company will initially be offering products based on separate formulations developed with distinct CBD and THC based components to the California market starting inQ1 of 2018 and will follow on with other US jurisdictions. These solutions will also be presented to the Canadian market when regulatory conditions take effect.**

**Of important note, the Company will only sell THC-based products under license to third parties in the U.S. until federal law pertaining to cannabis is changed. The primary manufacturing and marketing focus will instead be on CBD products derived from the highest quality CBD hemp certified as 'U.S. Farm Bill compliant' enabling the Company to stay completely aligned with U.S. federal law. This class of product may be sold in most U.S. states and in many countries around the world, and means that the Company is not adversely affected in any way by the recent revocation of the 'Cole memo' by the U.S. Department of Justice.**

**Under the terms of the Agreement, the Company will issue 9,500,000 common shares to the shareholders of RISE Research and buy out the current Canadian royalty agreement for a sum of \$250,000. RISE assets include cannabis commercial products based on patent pending formulations and processes currently filed with the U.S. Patent and Trademark Office. Beyond an approximate accounts payable value of \$100,000, RISE Research has no material liabilities.**

**Anton Mattadeen, who became a director of the Company on the acquisition of the original license, is an owner of Rise Research.**

8. Describe the acquisition of new customers or loss of customers.

**N/A**

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**N/A**

- 10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.  
**N/A**
- 11. Report on any labour disputes and resolutions of those disputes if applicable.  
**N/A**
- 12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.  
**N/A**
- 13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.  
**N/A**
- 14. Provide details of any securities issued and options or warrants granted.

<b>Security</b>	<b>Number Issued</b>	<b>Details of Issuance</b>	<b>Use of Proceeds<sup>(1)</sup></b>
Common shares	113,280	Warrant exercise	\$33,984 – working capital

*(1) State aggregate proceeds and intended allocation of proceeds.*

- 15. Provide details of any loans to or by Related Persons.  
**N/A**
- 16. Provide details of any changes in directors, officers or committee members.  
**N/A**
- 17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.  
**N/A**

## Certificate Of Compliance


The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there were is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated February 8, 2018\_\_\_\_\_.

Chris Carmichael\_\_\_\_\_

Name of Director or Senior  
Officer



Signature

CFO

Official Capacity

<b>Issuer Details</b>		For Month	Date of Report
Name of Issuer		End	YY/MM/D
Luminor Medical Technologies Inc.		January 2018	18/02/08
Issuer Address			
B2 – 125 The Queensway, Suite 217			
City/Province/Postal Code		Issuer Fax No.	Issuer Telephone No.
Toronto, ON M8Y 1H6		( )	(647) 225-4337
Contact Name		Contact Position	Contact Telephone No.
Chris Carmichael		CFO	(647) 225-4337
Contact Email Address		Web Site Address	
ccarmichael33@outlook.com			